연구용
제품 번호: S2730
화학 구조
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| A549 cells | Cell viability assay | 3.9-1000 nM | 72 h | a dose-dependent inhibition of cancer cell viability | 25328409 | |
| MV4-11 | Function assay | a decrease in mitochondrial matrix protein aconitase hydratase 2 (ACO2) | 25328409 | |||
| MV4-11 | Cytotoxicity assay | Cytotoxicity against human MV4-11 cells expressing FLT3 ITD mutant, IC50=0.0015μM | 31207462 | |||
| MOLM13 | Cytotoxicity assay | Cytotoxicity against human MOLM13 cells expressing FLT3 ITD mutant, IC50=0.0049μM | 31207462 | |||
| MV4-11 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human MV4-11 cells assessed as inhibition of cellular viability incubated for 72 hrs by CellTiter-Blue assay, IC50=0.012μM | 30742435 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | |||
| MV4-11 | Cytotoxicity assay | 0.5 to 5000 nM | 2 to 8 hrs | Cytotoxicity in human MV4-11 cells assessed as inhibition of cellular viability at 0.5 to 5000 nM incubated for 2 to 8 hrs followed by compound washout by CellTiter-Glo luminescent assay | 30742435 | |
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 443.54 | 화학식 | C26H29N5O2 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 670220-88-9 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | CP-868596, ARO 002 | Smiles | CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4 | ||
|
In vitro |
DMSO
: 88 mg/mL
(198.4 mM)
Ethanol : 88 mg/mL Water : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
FLT3
(CHO cells) 0.74 nM(Kd)
PDGFRα
(CHO cells) 2.1 nM(Kd)
PDGFRβ
(CHO cells) 3.2 nM(Kd)
|
|---|---|
| 시험관 내(In vitro) |
Crenolanib is significantly more potent in inhibiting the kinase activity of resistant PDGFRα kinases (D842I, D842V, D842Y, D1842-843IM, and deletion I843). This compound is more potent against D842V in the isogenic model system, with an IC50 of approximately 10 nM. It inhibits the kinase activity of the fusion oncogene in EOL-1 cell line, which is derived from a patient with chronic eosinophilic leukemia and expresses the constitutively activated FIP1L1- PDGFRα fusion kinase, with IC50 = 21 nM. This chemical also inhibits the proliferation of EOL-1 cells with IC50 = 0.2 pM. It inhibits the activation of V561D or D842V-mutant kinases expressed in BaF3 cells with IC50 with 85 nM or 272 nM, respectively. This compound inhibits PDGFRα activation in H1703 non-small cell lung cancer cell line which has 24-fold amplification of the 4q12 region that contains the PDGFRα locus, with IC50 with 26 nM. It is an orally bioavailable, highly potent and selective PDGFR TKI. This benzimidazole compound has IC50s of 0.9 nM and 1.8 nM for PDGFRA and PDGFRB, respectively. |
| 키나아제 분석 |
PDGFRα 키나아제 활성에 대한 생화학적 평가
|
|
중국 햄스터 난소(CHO) 세포에 돌연변이 또는 야생형 PDGFRα 구조체를 일시적으로 형질주입하고 다양한 농도의 Crenolanib(CP-868596)으로 처리한다. 재조합 DNA 관련 실험은 지침에 따라 생물안전 2등급 조건에서 수행한다. 세포주로부터 단백질 용해물을 준비하고 항-PDGFRα 항체를 사용하여 면역침강을 수행한 후 PDGFRα에 대한 순차적 면역블롯팅을 진행한다. Photoshop 소프트웨어를 사용하여 약물 효과를 정량화하기 위해 밀도계측을 수행하며, 인산화된 PDGFRα 수준을 총 단백질로 정규화한다. 밀도계측 및 증식 실험 결과는 Calcusyn 2.1 소프트웨어를 사용하여 분석하고 IC50 값을 수학적으로 결정한다. 특정 돌연변이에 대한 이 화합물의 IC50 값을 비교하기 위해 Wilcoxon Rank Sum Test를 사용한다.
|
|
| 생체 내(In vivo) |
This compound, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo |
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | pKIT / KIT pFLT3 / FLT3 / pERK / ERK / pS6 / S6 pAKT / AKT / pMAPK / MAPK / pSTAT5 / STAT5 |
|
24623852 |
| Growth inhibition assay | Cell viability |
|
24623852 |
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2026-04-09)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT03258931 | COMPLETED | Newly Diagnosed FLT3 Mutated AML |
Arog Pharmaceuticals, Inc. |
2018-08-15 | PHASE3 |
| NCT03250338 | COMPLETED | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations |
Arog Pharmaceuticals, Inc. |
2018-08-16 | PHASE3 |
| NCT02400255 | COMPLETED | Acute Myeloid Leukemia |
Arog Pharmaceuticals, Inc. |
2015-09 | PHASE2 |
| NCT02847429 | UNKNOWN | GIST With D842V Mutated PDGFRA Gene |
Arog Pharmaceuticals, Inc. |
2016-08 | PHASE3 |
| NCT03324243 | WITHDRAWN | Relapsed/Refractory FLT3-mutated AML |
Arog Pharmaceuticals, Inc. |
2018-01 | PHASE2 |
| NCT03193918 | COMPLETED | Esophagogastric Adenocarcinoma |
Arog Pharmaceuticals, Inc. |
2017-04-14 | PHASE1 |